Compare Figs Inc (FIGS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Smith & Nephew plc — how do they compare? Figs Inc trades at $14.96 (market cap $2.49B), while Smith & Nephew plc trades at $27.23 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 4.5× Figs Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Smith & Nephew plc for 120 Days on average.
| FIGS | SNN | |
|---|---|---|
Market Cap | $2.49B | $11.10B |
Volume | 5,964,311 | 1,051,703 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $37.17 |
52-Week Low | $6.90 | $26.42 |
Typical Hold Time | 33 Days | 120 Days |
Enterprise Value | $2.25B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $14.06, down 0.28% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $556M in 2024 to $631M in 2025, with net income surging to $34M. Recent quarters have consistently beaten EPS expectations, and international sales grew 67% in Q2 2026. Analyst consensus is bullish with a $18.00 price target suggesting 28% upside potential from current levels.
The outlook remains positive with accelerating growth and margin expansion, though the stock's rich valuation (P/E 42.6) presents risk if execution falters. Key catalysts include continued international expansion and sustained demand from healthcare professionals, while risks include premium valuation pressure and competitive threats in medical apparel.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
